Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

CervoMed presents interim 24-week NfL data for neflamapimod in nfvPPA at CTAD

Plasma neurofilament light chain stayed stable overall and fell at the highest drug exposures in the 19-patient US cohort of a Phase 2a trial, with no new safety signals.

16 Nov 2026 · CervoMed Inc. CRVO · Company news

CervoMed presented interim 24-week biomarker results on 16 November 2026 at the CTAD conference from its Phase 2a trial of oral neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA).

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): CervoMed Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →